How Does Wall Street Rate Shares Of BioMarin Pharmaceutical Inc. (BMRN)?

0
3

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw an upside of 1.29% to $115.29 after adding $1.47 on Wednesday. The 5-day average trading volume is 1,148,884 shares of the company’s common stock. It has gained $116.29 in the past week and touched a new high 5 times within the past 5 days. An average of 1,518,131 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,528,332.

BMRN’s 1-month performance is 8.79% or $11.25 on its low of $100.52 reached on 01/03/23. The company’s shares have touched a 52-week low of $70.73 and high of $114.80, with the stock’s rally to the 52-week high happening on 01/25/23. YTD, BMRN has achieved 9.98% or $12.10 and has reached a new high 10 times. However, the current price is up 0.43% from the 52-week high price.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Insider Transactions

BMRN stock investors last saw insider trading activity on Jan 17.BIENAIME JEAN JACQUES (Chief Executive Officer) most recently sold 10,000 shares at $111.55 per share on Jan 17. This transaction cost the insider $1,115,500. Chief Executive Officer, BIENAIME JEAN JACQUES, sold 10,000 shares at a price of $112.25 on Jan 13. Then, on Jan 13, EVP, Chief Financial Officer Mueller Brian sold 2,500 shares at a price of $114.50 per share. This transaction amounted to $286,250.

Valuation Metrics

BMRN stock has a beta of 0.36. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 10.39 while the price-to-book (PB) in the most recent quarter is 4.62, with the price to cash flow ratio at 314.59.

BioMarin Pharmaceutical Inc.’s quick ratio for the period ended September 29 was 3.50, with the current ratio over the same period at 5.10. In terms of profitability, the gross margin trailing 12 months is 76.30%. The firm’s gross profit as reported stood at $1.38 billion against revenue of $1.85 billion.

Earnings Surprise

For the quarterly period ending September 29 this year, BioMarin Pharmaceutical Inc.’s cash and short-term investments amounted to $512.25 million against total debt of $1.09 billion. Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -448.72% to -$6.65 million, while revenue of $27.66 million was 515.94% off the previous quarter. Analysts expected BMRN to announce -$0.01 per share in earnings in its latest quarter, but it posted -$0.04, representing a -300.00% surprise. EBITDA for the quarter stood at more than $23.06 million. BMRN stock balance sheet for the quarter ending September 29 shows that total liabilities totaled 1.7 billion, with total debt at $1.09 billion. Shareholders hold equity totaling $185.85 million.

Let’s look briefly at BioMarin Pharmaceutical Inc. (BMRN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 24 January was 70.83% to suggest the stock is trending Overbought, with historical volatility in this time period at 20.99%.

The stock’s 5-day moving average is $112.16, reflecting a +4.43% or $4.90 change from its current price. BMRN is currently trading +10.78% above its 20-day SMA, +29.59% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +38.73% and SMA200 by+38.68%.

Stochastic %K and %D was 87.36% and 79.04% and the average true range (ATR) pointed at 2.52. The RSI (14) points at 67.64%, while the 14-day stochastic is at 93.35% with the period’s ATR at 2.61. The stock’s 9-day MACD Oscillator is pointing at 1.45 and 2.57 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Canaccord Genuity launched coverage with a Hold rating. Analysts offering their rating for BMRN stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate BMRN as a “sell,”, while 4 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 4 rates the stock as overweight while 16 have offered a “buy” rating.

What is BMRN’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $83.00 and a high of $200.00, with their median price target at $120.00. Looking at these predictions, the average price target given by analysts is for BioMarin Pharmaceutical Inc. (BMRN) stock is $123.48.

LEAVE A REPLY

Please enter your comment!
Please enter your name here